Everyone know this is now a bogus statement.Under Algernon's "Reorganization" (100 to 1 Reverse Split) they have taken the pipeline backwards to Phase 1 studies. They already spend a lot of time at Phase 2 because they are not running Randomized Double-blind Placebo Controlled clinical trials. Just like the IPF/Chronic cough data will not move beyond Phase 2 no matter what the pending data suggests. You have stock pumpers coming to Algernon's aid hoping the stock recovers. "The benefit of this strategy is that it shortens the timeframe of the trials because they can generally skip the Phase 1 because they already know that the drug is safe, and they can get right into Phase 2 to identify whether it works or not," AlphaNorth Asset Management cofounder Steve Palmer told Streetwise Reports.